# Supplementary Figure 3 (Related to Figure 1)

Supplementary Figure 3. Related to Figure 1. Loss of *Prmt1* reduces gluconeogenesis capacity in the liver. *A*) Schematic of *Prmt1* deletion in *Prmt1*fl/fl mice after tail vein injection of adenoviral Cre recombinase. In this study, exon 4 and 5 of *Prmt1* were deleted. *B*) qPCR analyses of *Prmt1* mRNA levels in the liver of *Prmt1*fl/fl mice injected with indicated adenoviruses through tail vein (n = 5/group). *C*) Immunoblot analyses of PRMT1 in the liver of mice described in (*B*) (n = 2/group). HSP90 was used as a loading control. *D*) H&E-stained images (scale bar, 100 μm) of liver of *Prmt1*fl/fl mice after tail vein injection of indicated adenoviruses. *E*) Blood glucose levels in 6 hour- and 16 hour-fasted *Prmt1*fl/fl mice after tail vein injection of indicated adenoviruses (n = 5/group). *F*) qPCR analyses of *Prmt1* and gluconeogenic marker mRNA levels in the liver of 16 hour-fasted mice described in (*E*) (n = 5/group). *G*) qPCR analyses of proliferation, inflammation, cell death, oxidative stress response, and fibrosis marker mRNA levels in in the liver of 16 hour-fasted mice described in (*E*) (n = 5/group). *H*) PTT in 16 hour-fasted mice described in (*E*) (n = 5 for Ad-GFP, n = 6 for Ad-Cre). AUC, area under the curve. *I*) qPCR analyses of *Prmt1* in the primary hepatocytes isolated from *Prmt1*fl/fl mice after tail vein injection of indicated adenoviruses (n = 4/group). *J*) qPCR analyses of gluconeogenic marker mRNA levels in the primary hepatocytes isolated from *Prmt1*fl/fl mice after tail vein injection of indicated adenoviruses and stimulated with vehicle (Ctrl) or 200 nM glucagon for 3 hours (n = 5/group for Ad-GFP infected groups, n = 4/group for Ad-Cre infected groups). Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. n.s., not significant. 2-tailed Student's *t* test (B, E-I) or 2-way ANOVA (J).